Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vbi Vaccines Inc CS (NQ: VBIV ) 0.0653 UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vbi Vaccines Inc CS < Previous 1 2 3 4 Next > VBI Vaccines Provides an Update on its Restructuring Proceedings August 02, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives July 30, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Results of Annual General Meeting June 25, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients May 29, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients May 22, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Reports First Quarter 2024 Financial Results May 15, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Reports Full Year 2023 Financial Results April 16, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 11, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 09, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma April 03, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform April 02, 2024 From VBI Vaccines Inc. Via Business Wire VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences February 14, 2024 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting November 20, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Reports Third Quarter 2023 Financial Results November 14, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program October 26, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern September 27, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM September 07, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B September 06, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Reports Second Quarter 2023 Financial Results August 14, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares July 24, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults July 19, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering July 06, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants July 05, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties July 05, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Results of Annual General Meeting June 23, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults June 15, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Poster Presentation at EASL 2023 June 07, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Reports First Quarter 2023 Financial Results May 15, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Appoints Vaughn Himes to Board of Directors April 25, 2023 From VBI Vaccines Inc. Via Business Wire VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split April 04, 2023 From VBI Vaccines Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.